Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage

Publisher Website
Google Scholar
Abstract
A clinical trial of .epsilon.-aminocarproic acid (EACA) in preventing recurrent hemorrhage from intracranial arterial aneurysms is reported. Previous reports were reviewed, and their results concerning antifibrinolytic agents were inconclusive in establishing their efficacy. Patients (100) with documented ruptured intracranial aneurysms were admitted to this study within 48 h of the initial hemorrhage; 45 patients received 36 g of EACA/day, with 11 documented rebleeds and 1 suspected rebleed; 55 patients did not receive EACA, and there were 4 documented rebleeds and 1 suspected rebleed. No benefit was seen from the use of EACA.